Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy

Last updated: February 26, 2025
Sponsor: Sun Yat-sen University
Overall Status: Active - Recruiting

Phase

2

Condition

Effects Of Chemotherapy

Neutropenia

Treatment

Telpegfilgrastim

Clinical Study ID

NCT06857292
Telpegfilgrastim
  • Ages 14-18
  • All Genders

Study Summary

This study is a multicenter, single-arm, prospective study. The study population includes children with cancer who require high-intensity chemotherapy. The study aims to evaluate the safety and effectiveness of Telpegfilgrastim in preventing neutropenia in children with cancer (neuroblastoma, sarcoma, lymphoma, etc.) undergoing chemotherapy, while also studying the pharmacokinetic characteristics of Telpegfilgrastim in children with cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with 14≤ age < 18 years;

  • Newly diagnosed patients with non-myeloid malignancies who are confirmed byhistopathology or cytology to require intensive chemotherapy (first course ofchemotherapy or second course of chemotherapy);

  • Primary prevention (G-CSF 24 to 72 hours after the first use ofchemotherapy agents with myelosuppression to prevent the occurrence offebrile neutropenia (FN)) or secondary prevention (if FN ordose-restricted neutropenia occurred in a patient during a previouschemotherapy cycle) is required. Prophylactic use of G-CSF can beconsidered for the next chemotherapy cycle.

Febrile neutropenia (FN) : Oral temperature >38.3 ° C (axillary temperature >38.1 ° C) or oral temperature >38.0 ° C (axillary temperature >37.8 ° C) with ANC<0.5×10^9/L for 2 consecutive measurements within 2 hours, or ANC is expected to decrease to <0.5×10^9/L within 48 hours.

  • KPS score ≥50 or Lansky (LPS) score ≥50;

  • Normal hematopoietic function of bone marrow (ANC≥1.5×10^9/L, PLT≥80×10^9 /L,Hb≥75g/L, WBC≥3.0×10^9/L, and not exceeding the upper limit of normal value);

  • Life expectancy of at least 6 months; ⑦ Obtain written informed consent.

Exclusion

Exclusion Criteria:

  • Received any rhG-CSF within 3 weeks prior to study participation;

  • Received any antibody coupling drug (ADC) drugs with potential blood toxicitywithin 3 weeks before participating in the study;

  • Recipients of hematopoietic stem cell transplantation or organtransplantation;

  • Clinical trials of other drugs were being conducted within 2 monthsbefore enrollment;

  • There is no control of infection, body temperature ≥38℃; ⑥ Liverfunction test: total bilirubin (TBIL) alanine aminotransferase (ALT.) and aspartate aminotransferase (AST.) were more than 2.5times the upper limit of normal value; ⑦ Renal function test:serum creatinine (Cr.) > 1.5 times the upper limit of normalvalue; ⑧Other conditions considered by the researchers to becontraindications for this study.

Study Design

Total Participants: 97
Treatment Group(s): 1
Primary Treatment: Telpegfilgrastim
Phase: 2
Study Start date:
December 01, 2024
Estimated Completion Date:
December 31, 2025

Study Description

Compared with the currently available straight chain PEG-rhG-CSF, the structure of its Y-type branch chain affects the activity and metabolic rate of the drug to a certain extent. While prolonging the half-life of the drug, the dosage of the drug is also significantly lower than that of the long-acting products on the market. It can be prophylactically administered once after chemotherapy to maintain the effective blood concentration of the whole cycle and effectively prevent the occurrence of neutropenia. Due to the reduction of the dose, the incidence of side effects such as musculoskeletal pain is correspondingly reduced, and there may be a better safety. At the same time, the accessibility of clinical PEG-rhG-CSF can be further solved, and the treatment cost is also expected to decrease, so that more patients can benefit from PEG-rhG-CSF.

Telpegfilgrastim was approved on June 30, 2023 for "reducing the incidence of infection characterized by febrile neutropenia in patients with non-myeloid malignants who are treated with myelosuppressive anticancer agents that tend to cause clinically significant febrile neutropenia." At present, although Telpegfilgrastim has been approved for neutropenia induced by chemotherapy for non-myeloid malignant tumors, the safety and efficacy data in pediatric patients are lacking, and the pharmacokinetic characteristics in children are still unclear. The aim of this study was to evaluate the safety and efficacy of Telpegfilgrastim in the prevention of neutropenia in pediatric cancer patients receiving chemotherapy, and to investigate the pharmacokinetics of Telpegfilgrastim in pediatric cancer patients.

Connect with a study center

  • SunYat-senU

    Guangzhou, Guangdong 510060
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.